MabVax Therapeutics Holdings (MBVX) Is Up Sharply On License Agreement

MabVax Therapeutics Holdings (MBVX) announced Monday morning that it has signed an asset purchase and license agreement with Boehringer Ingelheim.

MabVax Therapeutics gapped open sharply higher this morning and is now up 1.75 at $2.34 on the highest volume of the year. The stock has broken out to over a 4-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT